Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of N-Acetylcysteine with Pirfenidone in IPF
NCT02707640Phase 2Completed
- Sponsor
- Roche
- Start
- Aug 2013
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing N-Acetylcysteine Arm with Placebo Arm (2 arms). Primary endpoints: Percentage of Participants With Dose Reductions at 24 weeks, Percentage of Participants With Early Treatment Discontinuations at 24 weeks and 5 more. Started Aug 2013; status: completed.
02
Drugs
acetylcysteine
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT02707640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02707640.